Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Syst-Onco-Herpes

Financiado

Cerrado

Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer speci...

Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer specific receptors. Virus optimization and business planning. Solid tumors, in particular metastatic ones, represent unmet clinical needs and the second cause of death worldwide. Oncolytic viruses (OVs) kill tumors and spare normal cells. They are a distinct class of novel anti-cancer agents... ver más

31/10/2023

Confindustria Emil...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

CONFINDUSTRIA EMILIA AREA CENTRO, LE IMPRESE... No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-31

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Confindustria Emilia Area Ce...

125.00K€ | Lider

UNIBO

25.00K€ | Participante

Proyectos interesantes

PID2020-119692RB-C21

Medical Technol...

Biotechnology

266K€ Cerrado

BIO2017-89754-C2-1-R

Medical Technol...

Biotechnology

254K€ Cerrado

TRASTUZUCRAD

Medical Technol...

Biotechnology

2M€ Cerrado

BIO2008-04692-C03-01

Medical Technol...

Biotechnology

151K€ Cerrado

I-CREATE

Medical Technol...

Biotechnology

5M€ Cerrado

BIO2014-57716-C2-1-R

Medical Technol...

Biotechnology

272K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2022-04-13
Fecha Fin: 2023-10-31

Líder del proyecto

CONFINDUSTRIA EMILIA AREA CENTRO, LE IMPRESE... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Solid tumors, in particular metastatic ones, represent unmet clinical needs and the second cause of death worldwide. Oncolytic viruses (OVs) kill tumors and spare normal cells. They are a distinct class of novel anti-cancer agents, frequently administered by intratumoral injection. A Holy Grail in the innovation of OVs is the possibility to administer them by systemic, e.g. intravenous injection, so that in the human body OVs search for metastases and scavenge them. The systemic delivery of OVs tackles societal challenges as it meets the needs of metastatic patients, those who die of cancer and need innovative therapies most. The Principal Investigator has generated a family of innovative oncolytic herpesviruses (ReHVs) which specifically target HER2-positive tumors (HER2-ReHVs). In preclinical studies HER2-ReHVs exhibit high specificity for HER2-positive cancers, high anti-tumor efficacy also against metastatic tumors, vaccinate against metastatic-like tumors, and are highly safe. These properties position ReHVs for systemic delivery. The ReHV technology is protected by a portfolio of patents. The objectives of this Proposal are twofold. Firstly, to improve the systemic delivery of ReHVs by identifying the obstacles that constrain such administration, to develop novel strategies to overcome them, including high-risk high-gain modifications that make ReHVs better suited for the systemic delivery. Secondly, to carry out initiatives for the technological transfer, i.e. development and commercialization of ReHVs. These include the detailed planning of activities to take ReHVs to the authorization for a First-in-Human clinical experimentation, to develop a business plan and carry out OV market analysis and search for investors. By combining the Development and commercialization initiatives with the technological advancements, this POC is expected to achieve the broader objective of progressing ReHVs into clinical experimentation and ultimately to bring them to patients

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores